Interested in all things mycobacteria and cool science broadly. Ass. Prof at the Univ. of Western Ontario. Editor for Microbiology. Views are mine. @[email protected], @pmoyniha
https://pmoyniha.github.io/moynihan-lab/
Patrick Moynihan
Loading...
The Thermo Fisher situation keeps getting worse. We've now collected 450+ problematic images presented as verification data in TF's antibody catalog. This includes:
🖌️ Dozens more images with duplications or painting
🖨️ Hundreds of blots that all share the same background (behold slideshow below)
Video
Reese Richardson
Of all the harm this administration has done to US science, today's proposed changes to the way federal grants are awarded and administered is the most damaging yet.
The text of the federal register document is impenetrably tedious by design, so here's an excellent summary of what it says.
This is super cool. Perhaps finally pointing towards a purpose for vaults?
TL;DR: We've identified more than 100 cases of apparent manipulation in Thermo Fisher Scientific's antibody verification data.
@sholtodavid.bsky.social @johanduchene.bsky.social
reeserichardson.blog/2026/05/28/h...
@johanduchene.bsky.social @sholtodavid.bsky.social
Spent the last hour looking, found ten more apparently manipulated Western blots in Thermo Fisher's antibody verification data (across eight different catalogued products). Thread below.
www.thermofisher.com/antibody/pro...
Patrick Moynihan
We’ve documented more than 100 instances of apparent data manipulation in Thermo’s catalog
Via @madhupai.bsky.social:
"...every US$1 invested in TB yields $46 in benefits."
"Greater investments by high-burden countries make them less reliant on development assistance and more likely to have a sustainable TB response"
Surprised to discover that Thermo Fisher appears to show a fake western blot for the validation of one of their p53 antibodies. I've added a diagram to show the very similar bands. This does not appear to be one of the "published figures" but their own internal data.
Sholto David
Amit Chandra, MD
CIHR has launched a trial ballon that suggests shifting to one competition a year. This is the worst idea I have heard in a long time. The only benefit is making top-line success rates look better than they are. Keep it as is, do in-person reviews, and keep the pain in the open.
